These are reviewed studies whose abstracts concern Mesonephric Adenocarcinoma. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Mesonephric Adenocarcinoma. Most are early lab, animal, or small human studies, and findings often conflict.
3 studies3 human⚠ Conflicting evidenceMechanism (2)
Tracking 3 published studies of Mesonephric Adenocarcinoma: 3 in humans.
Reported direction across studies: 2 positive, 1 negative.
Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.
These counts summarize what the studies reported; they are not a measure of whether anything works for Mesonephric Adenocarcinoma.
Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 48
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · Nov 2025 · case series
mesonephric adenocarcinomamesonephric-like adenocarcinomaclear cell carcinomamesonephric carcinosarcoma
The authors performed Napsin-A immunohistochemistry on whole-slide sections from 48 mesonephric and mesonephric-like adenocarcinomas and carcinosarcomas. Napsin-A was positive in 17/48 cases (35.4%), with focal granular cytoplasmic staining in 1–40% of cells; positivity occurred in 13/32 MLAs, 2/13 MAs, and 2/3 carcinosarcomas. The study concludes that Napsin-A is expressed in a substantial subset of these tumors and that reliance on a single marker could lead to misclassification as clear cell carcinoma.
Reported effects: Napsin-A positive overall 35.4%, n=48 · Range of focal granular cytoplasmic expression · +3 more
Key findings
- Napsin-A staining was positive in 17 of 48 cases (35.4%), with focal granular cytoplasmic expression ranging from 1% to 40%.
- 13/32 (40.6%) mesonephric-like adenocarcinomas (MLAs) were Napsin-A positive.
- 2/13 (15.4%) mesonephric adenocarcinomas (MAs) were Napsin-A positive.
- 2/3 (66.7%) mesonephric or mesonephric-like carcinosarcomas were Napsin-A positive.
- Because of morphologic and immunohistochemical overlap, Napsin-A expression in MA/MLA may contribute to misclassification as clear cell carcinoma.
Limitations: Observational pathology series without reported clinical outcome correlation; Relatively small overall sample size and very small subgroup sizes (e.g., n=3 carcinosarcomas); Findings are based solely on immunohistochemistry on tissue sections; no clinical or molecular correlation reported in the abstract.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 6
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · Jan 2023 · case series
mesonephric adenocarcinomamesonephric-like adenocarcinomaurinary tracturinary bladderperirenal regionureteruterine cervixovaryendometrium
This study reports a case series of six mesonephric (MA) or mesonephric-like (MLA) adenocarcinomas arising in the urinary tract and describes their morphology, immunophenotype, and limited molecular findings. All six tumors were Pax8-positive and showed a luminal pattern of CD10 staining (CD10 unavailable in one case); a KRAS G12C mutation was found in one case, and other tested hotspot mutations were absent. The authors propose classifying urinary-tract tumors with mesonephric remnants as MA and those associated with Müllerian-type precursors as MLA.
Reported effects: MA in urinary bladder cases 4, n=6 · MA in perirenal region cases 1, n=6 · +4 more
Key findings
- Characterized 4 cases of MA in the urinary bladder (1 woman and 3 men), 1 case of MA in the perirenal region (woman), and 1 case of MLA in the ureter (woman).
- All cases (6/6) were diffusely positive for Pax8.
- All displayed a luminal pattern of CD10 staining, except case 4 for which CD10 immunostain was not available for review.
- GATA3 expression was variable: focally positive in cases 1, 2, and 6; negative in case 3; diffusely positive in case 5.
- TTF-1 was diffusely expressed in cases 1 and 3 and negative in cases 2, 5, and 6.
- A KRAS G12C somatic mutation was detected in case 6; hotspot mutations in KRAS, NRAS, and PIK3CA were not present in other tested cases.
- Authors conclude urinary-tract MAs and MLAs share morphology and immunophenotype with their counterparts in the female genital tract and propose a classification based on origin (mesonephric remnants/Wolffian vs Müllerian-type precursors).
Limitations: Very small number of cases (n=6).; Retrospective case series without systematic clinical outcome or follow-up data reported.; Molecular testing appears limited (hotspot testing reported) and not uniformly applied to all cases.; One case lacked CD10 immunostain availability, limiting uniform immunophenotypic assessment..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Human · observationalReported negativeModerate evidenceTier 3 · early humann = 99
The American journal of surgical pathology · Apr 2021 · multi-institutional case series
mesonephric adenocarcinoma (uterine cervix)mesonephric-like adenocarcinoma (endometrium)mesonephric-like adenocarcinoma (ovary)
This multi-institutional study reviewed 99 well-defined cases of mesonephric and mesonephric-like adenocarcinomas of the gynecologic tract and described clinicopathologic features. Most tumors presented at an advanced stage and over half developed recurrences, which were most often distant. Five-year disease-specific survival was 74% for cervical MA, 72% for endometrial MLA, and 71% for ovarian MLA.
Reported effects: advanced stage (II to IV) presentation, MA of the cervix 60%, n=25 · advanced stage (II to IV) presentation, MLA of the endometrium 58%, n=43 · +11 more
Key findings
- Majority presented at advanced stage (II to IV): 15/25 (60%) MA of the cervix, 25/43 (58%) MLA of the endometrium, and 7/18 (39%) MLA of the ovary.
- Overall recurrence occurred in 46/89 (52%) of cases.
- Recurrence rates by site: 12/24 (50%) MA of the cervix, 24/41 (59%) MLA of the endometrium, and 10/24 (42%) MLA of the ovary.
- When recurrence occurred, it was most commonly distant: 9/12 (75%) MA of the cervix, 22/24 (92%) MLA of the endometrium, and 5/9 (56%) MLA of the ovary.
- Five-year disease-specific survival was 74% (n=26) for MA of the cervix, 72% (n=43) for MLA of the endometrium, and 71% (n=23) for MLA of the ovary.
- The authors conclude mesonephric neoplasms are a clinically aggressive group with a predilection for pulmonary recurrence.
Limitations: Observational case series design with potential selection bias inherent to retrospective multi-institutional cohorts.; Subgroup sample sizes are small for some analyses (for example ovarian MLA denominators of 18-24 cases), limiting precision.; Abstract does not report treatment details, follow-up duration, or statistical analyses.; No control or comparator group reported..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text